Drug intelligence / Profile preview

DA-001

Development stage: Phase 3
Lead developer: Jupiter Wellness
Modality: Small Molecules
Administration: Topical

Overview

**DA-001** is an investigational topical fixed-dose combination developed by Applied Biology for hair-shedding reduction and hair regrowth. The product is described in its registered clinical study as topical phenylephrine, an alpha-1 adrenergic receptor agonist, combined with tyramine, a trace amine-associated receptor agonist. It is being evaluated for telogen effluvium and androgenetic-pattern hair loss, including female pattern hair loss and male pattern baldness.

Brand names: Intact Pro
Other names: Phenylephrine 0.25% + Intact Pro

Targets

ADRA1 (Alpha-1 adrenergic receptor family)TAAR1 (Trace amine-associated receptor 1)

Beyond the preview

Go deeper on DA-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-001.

Explore the full profile